Keith W Woods
Overview
Explore the profile of Keith W Woods including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woods K, Lai C, Miyashiro J, Tong Y, Florjancic A, Han E, et al.
Bioorg Med Chem Lett
. 2012 Feb;
22(5):1940-3.
PMID: 22326396
We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (K(i)) less than 1nM. Kinase selectivity...
2.
Miyashiro J, Woods K, Park C, Liu X, Shi Y, Johnson E, et al.
Bioorg Med Chem Lett
. 2009 Jun;
19(15):4050-4.
PMID: 19553114
Based on screening hit 1, a series of tricyclic quinoxalinones have been designed and evaluated for inhibition of PARP-1. Substitutions at the 7- and 8-positions of the quinoxalinone ring led...
3.
Liu X, Shi Y, Woods K, Hessler P, Kroeger P, Wilsbacher J, et al.
Neoplasia
. 2008 Aug;
10(8):828-37.
PMID: 18670641
Both Akt and Aurora A kinase have been shown to be important targets for intervention for cancer therapy. We report here that Compound A (A-443654), a specific Akt inhibitor, interferes...
4.
Johnson E, Stewart K, Woods K, Giranda V, Luo Y
Biochemistry
. 2007 Jul;
46(33):9551-63.
PMID: 17655330
PLK1 (polo-like kinase 1) is a key mitotic kinase and a therapeutic target in the treatment of proliferative diseases. Here we investigate the relative substrate specificity and pharmacological relatedness of...
5.
Zhu G, Gandhi V, Gong J, Thomas S, Woods K, Song X, et al.
J Med Chem
. 2007 May;
50(13):2990-3003.
PMID: 17523610
Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising efficacy was observed...
6.
Woods K, Fischer J, Claiborne A, Li T, Thomas S, Zhu G, et al.
Bioorg Med Chem
. 2006 Jul;
14(20):6832-46.
PMID: 16843670
A series of heteroaryl-pyridine containing inhibitors of Akt are reported. The synthesis and structure-activity relationships are discussed, leading to the discovery of a indazole-pyridine analogue (K(i)=0.16 nM). These compounds bind...
7.
Thomas S, Li T, Woods K, Song X, Packard G, Fischer J, et al.
Bioorg Med Chem Lett
. 2006 May;
16(14):3740-4.
PMID: 16678413
Based on lead compounds 2 and 3 a series of 3,5-disubstituted pyridines have been designed and evaluated for inhibition of AKT/PKB. Modifications at the 3 position of the pyridine ring...
8.
Zhu G, Gong J, Claiborne A, Woods K, Gandhi V, Thomas S, et al.
Bioorg Med Chem Lett
. 2006 Apr;
16(12):3150-5.
PMID: 16603355
The structure-activity relationships of a series of isoquinoline-pyridine-based protein kinase B/Akt antagonists have been investigated in an effort to improve the major short-comings of the lead compound 3, including poor...
9.
Li Q, Woods K, Thomas S, Zhu G, Packard G, Fisher J, et al.
Bioorg Med Chem Lett
. 2006 Jan;
16(7):2000-7.
PMID: 16413780
Structure-based design and synthesis of the 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC(50) of 1.3nM against Akt1. Compound 13a shows...
10.
Shi Y, Liu X, Han E, Guan R, Shoemaker A, Oleksijew A, et al.
Neoplasia
. 2005 Dec;
7(11):992-1000.
PMID: 16331885
Akt is a serine/threonine kinase that transduces survival signals from survival/growth factors. Deregulation and signal imbalance in cancer cells make them prone to apoptosis. Upregulation or activation of Akt to...